Cell death and immunity in cancer: From danger signals to mimicry of pathogen defense responses

Immunological Reviews, Journal Year: 2017, Volume and Issue: 280(1), P. 126 - 148

Published: Oct. 13, 2017

Summary The immunogenicity of cancer cells is an emerging determinant anti‐cancer immunotherapy. Beyond developing immunostimulatory regimens like dendritic cell‐based vaccines, immune‐checkpoint blockers, and adoptive T‐cell transfer, investigators are beginning to focus on the immunobiology dying its relevance for success anticancer immunotherapies. It currently accepted that may die in response therapies through regulated cell death programs, which either repress or increase their immunogenic potential. In particular, induction ( ICD ), hallmarked by emission damage‐associated molecular patterns (DAMPs); molecules analogous pathogen‐associated (PAMPs) acting as danger signals/alarmins, great therapy. These ‐associated signals favor immunomodulatory responses lead tumor‐associated antigens (TAAs)‐directed immunity, paves way removal residual, treatment‐resistant cells. also succumbing can orchestrate “altered‐self mimicry” i.e. mimicry pathogen defense responses, levels nucleic acids and/or chemokines (resulting type I interferon/ IFN response‐like neutrophil activity). this review, we exhaustively describe main molecular, immunological, preclinical, clinical aspects immunosuppressive (with respect apoptosis, necrosis necroptosis). We provide extensive historical background these fields, with special attention self/non‐self models, have shaped field immunology.

Language: Английский

---

Combinatorial Strategies for the Induction of Immunogenic Cell Death

Frontiers in Immunology, Journal Year: 2015, Volume and Issue: 6

Published: April 24, 2015

The term "immunogenic cell death" (ICD) is commonly employed to indicate a peculiar instance of regulated death (RCD) that engages the adaptive arm immune system. inoculation cancer cells undergoing ICD into immunocompetent animals elicits specific response associated with establishment immunological memory. Only few agents are intrinsically endowed ability trigger ICD. These include chemotherapeutics routinely in clinic, like doxorubicin, mitoxantrone, oxaliplatin, and cyclophosphamide, as well some have not yet been approved for use humans. Accumulating clinical data activation responses against dying improved disease outcome patients affected by various neoplasms. Thus, novel therapeutic regimens urgently awaited. Here, we discuss current combinatorial approaches convert otherwise non-immunogenic instances RCD bona fide

Language: Английский

---

Recent advances in nanomaterial-based synergistic combination cancer immunotherapy

Chemical Society Reviews, Journal Year: 2019, Volume and Issue: 48(14), P. 3771 - 3810

Published: Jan. 1, 2019

This review aims to summarize various synergistic combination cancer immunotherapy strategies based on nanomaterials.

Language: Английский

---

Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death

Frontiers in Immunology, Journal Year: 2015, Volume and Issue: 6

Published: Nov. 20, 2015

The immunogenicity of malignant cells has recently been acknowledged as a critical determinant efficacy in cancer therapy. Thus, besides developing direct immunostimulatory regimens, including dendritic cell-based vaccines, checkpoint-blocking therapies, and adoptive T-cell transfer, researchers have started to focus on the overall immunobiology neoplastic cells. It is now clear that can succumb some anticancer therapies by undergoing peculiar form cell death characterized an increased immunogenic potential, owing emission so-called "damage-associated molecular patterns" (DAMPs). DAMPs other factors succumbing (ICD) favors establishment productive interface with immune system. This results elicitation tumor-targeting responses associated elimination residual, treatment-resistant cells, well immunological memory. Although ICD precision since its discovery, several questions remain be addressed. Here, we summarize tabulate main molecular, immunological, preclinical, clinical aspects ICD, attempt capture essence this phenomenon, identify future challenges for rapidly expanding field investigation.

Language: Английский

---

Colorectal Cancer Immunotherapy: Options and Strategies

Frontiers in Immunology, Journal Year: 2020, Volume and Issue: 11

Published: Sept. 18, 2020

Colorectal cancer is the third most common in world with increasing incidence and mortality rates globally. Standard treatments for colorectal have always been surgery, chemotherapy radiotherapy which may be used combination to treat patients. However, these many side effects due their non-specificity cytotoxicity towards any cells including normal that are growing dividing. Furthermore, patients succumb relapse even after a series of treatments. Thus, it crucial more alternative effective CRC Immunotherapy one new alternatives treatment. The strategy utilize patients' own immune system combating cells. Cancer immunotherapy overcomes issue specificity major problem radiotherapy. no antigen not affected. outcome some astonishing cases but not, rely on status system. Those who responded well immunotherapy, better prognostic quality life.

Language: Английский

---

Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition)

European Journal of Immunology, Journal Year: 2021, Volume and Issue: 51(12), P. 2708 - 3145

Published: Dec. 1, 2021

Abstract The third edition of Flow Cytometry Guidelines provides the key aspects to consider when performing flow cytometry experiments and includes comprehensive sections describing phenotypes functional assays all major human murine immune cell subsets. Notably, contain helpful tables highlighting differences between cells. Another useful feature this is analysis clinical samples with examples applications in context autoimmune diseases, cancers as well acute chronic infectious diseases. Furthermore, there are detailing tips, tricks pitfalls avoid. All written peer‐reviewed by leading experts immunologists, making an essential state‐of‐the‐art handbook for basic researchers.

Language: Английский

---

First oncolytic virus approved for melanoma immunotherapy

OncoImmunology, Journal Year: 2015, Volume and Issue: 5(1), P. e1115641 - e1115641

Published: Dec. 8, 2015

On 2015, October 27th, the US Food and Drug Administration (FDA) has officially approved talimogene laherparepvec (T-VEC, also known as OncoVEXGM-CSF) for use in melanoma patients with injectable but non-resectable lesions skin lymph nodes. T-VEC (which is commercialized by Amgen, Inc. under name of Imlygic®) becomes therefore first oncolytic virus cancer therapy US.

Language: Английский

---

Activating autophagy to potentiate immunogenic chemotherapy and radiation therapy

Nature Reviews Clinical Oncology, Journal Year: 2016, Volume and Issue: 14(4), P. 247 - 258

Published: Nov. 15, 2016

Language: Английский

---

Natural and therapy-induced immunosurveillance in breast cancer

Nature Medicine, Journal Year: 2015, Volume and Issue: 21(10), P. 1128 - 1138

Published: Oct. 1, 2015

Language: Английский

---

Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy

OncoImmunology, Journal Year: 2015, Volume and Issue: 4(4), P. e1008866 - e1008866

Published: March 2, 2015

The term "immunogenic cell death" (ICD) is now employed to indicate a functionally peculiar form of apoptosis that sufficient for immunocompetent hosts mount an adaptive immune response against dead cell-associated antigens. Several drugs have been ascribed with the ability provoke ICD when as standalone therapeutic interventions. These include various chemotherapeutics routinely in clinic (e.g., doxorubicin, epirubicin, idarubicin, mitoxantrone, bleomycin, bortezomib, cyclophosphamide and oxaliplatin) well some anticancer agents are still under preclinical or clinical development microtubular inhibitors epothilone family). In addition, few able convert otherwise non-immunogenic instances death into bona fide ICD, may therefore be chemotherapeutic adjuvants within combinatorial regimens. This case cardiac glycosides, like digoxin digitoxin, zoledronic acid. Here, we discuss recent developments on chemotherapy based inducers.

Language: Английский

---